|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:tenofovir
|
|
gptkbp:activities
|
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Viread
|
|
gptkbp:can_be_used_with
|
gptkb:efavirenz
gptkb:rilpivirine
gptkb:emtricitabine
|
|
gptkbp:clinical_trial
|
Phase III
pre-exposure prophylaxis (Pr EP)
|
|
gptkbp:contraindication
|
renal impairment
|
|
gptkbp:counseling_services
|
take with or without food
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
gptkb:tablet
300 mg
|
|
gptkbp:formulation
|
tenofovir disoproxil fumarate/efavirenz
tenofovir disoproxil fumarate/emtricitabine
tenofovir disoproxil fumarate/rilpivirine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tenofovir disoproxil fumarate
|
|
gptkbp:ingredients
|
C19 H30 N5 O10 P
|
|
gptkbp:interacts_with
|
gptkb:atazanavir
gptkb:didanosine
gptkb:rifampin
lopinavir/ritonavir
|
|
gptkbp:is_atype_of
|
J05 A F07
|
|
gptkbp:is_used_for
|
treatment of HIV
treatment of hepatitis B
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
excreted in urine
inhibits viral replication
bioavailability 25%
half-life 17 hours
|
|
gptkbp:provides_information_on
|
recommended in ART regimens
|
|
gptkbp:requires
|
gptkb:stock_market_index
|
|
gptkbp:safety_features
|
monitor renal function
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
lactic acidosis
bone density loss
hyperlipidemia
hepatotoxicity
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
202138-50-9
|